MedPath

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

Not Applicable
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Bipolar Disorder
Major Depression
Interventions
Procedure: genetic analysis
Procedure: genetic assay
Registration Number
NCT00178932
Lead Sponsor
Northwestern University
Brief Summary

The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
37
Inclusion Criteria

Patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder.

Exclusion Criteria

Patients with DSM-IV diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
2 Outcome in schizophrenia with other Antipsychoticsgenetic analysisOther Antipsychotics
1 Outcome in schizophrenia with certain antipsychoticgenetic assayclozapine
1 Outcome in schizophrenia with certain antipsychoticgenetic analysisclozapine
2 Outcome in schizophrenia with other Antipsychoticsgenetic assayOther Antipsychotics
Primary Outcome Measures
NameTimeMethod
We plan to compare the polymorphisms across schizophrenic patients and adults who do not have a diagnosed major mental illness. .single visit
Secondary Outcome Measures
NameTimeMethod
We will also evaluate relationships between the polymorphism and past and current mental health among the non-diagnosed samplesingle visit

Trial Locations

Locations (1)

Psychiatric Hospital at Vanderbilt

🇺🇸

Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath